Clinical role of PET/CT in distinguishing malignant from benign pleural effusion in non-small cell lung cancer?

Weishan ZHANG,Xiaoyi DUAN,Youmin GUO,Yan LI,Jian YANG
DOI: https://doi.org/10.19732/j.cnki.2096-6210.2019.04.008
2019-01-01
Abstract:Objective: To explore the clinical role of 18F-FDG PET/CT in distinguishing malignant from benign pleural effusion in pretreatment non-small cell lung cancer (NSCLC) patients. Methods: The NSCLC patients with pleural effusion who underwent PET/CT were retrospectively reviewed. Malignant or benign pleural effusion was confirmed with thoracentesis or biopsy. When the standard uptake value (SUV) of pleural was higher than 2.5 (SUV>2.5) or pleural activity was higher than mediastinal background (pleural SUV>aorta SUV), pleural effusion was diagnosed as malignant. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET/CT for detecting malignant pleural metastases were calculated. Results: Forty-six patients were enrolled, and 39 were malignant. For SUV>2.5, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET/CT were 76.9%, 100.0%, 100.0%, 43.8%, and 80.4%; and 89.7%, 100.0%, 100.0%, 63.6% and 91.3% for pleural SUV>aorta SUV, respectively. The areas under curve of receiver operating characteristic (ROC) curve were 0.961 and 0.972, respectively. Conclusion: 18F-FDG PET/CT can play a significant role in distinguishing malignant from benign pleural effusion in pretreatment NSCLC patients. The diagnostic accuracy could be improved when pleural activity higher than mediastinal background that used as diagnostic criteria.
What problem does this paper attempt to address?